A bit of intellectual property indiscretion has led to the retraction of a paper by Korean scientists. Although the details are fuzzy, several of the authors are affiliated with a Korean pharma company called SK.
The paper, “A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons,” was published in the The Korean Journal of Physiology & Pharmacology earlier this year.
According to the retraction notice: Continue reading Loose lips sink paper on company’s experimental pain drug